Monotherapy (first-choice drug) for: partial seizures with or without secondary generalization in adults and adolescents aged 16 and older who were first diagnosed with epilepsy. As an additional therapy for: partial seizures with or without secondary generalization in adults and children aged 1 month and older with epilepsy; myoclonic seizures in adults and adolescents aged 12 years and older, with juvenile myoclonic epilepsy; primary generalized tonic-clonic seizures in adults and adolescents aged 12 years and older, patients with idiopathic generalized epilepsy.
Levetiracetam tablets Composition
Active substance: levetiracetam;
1 tablet contains 250 mg, 500 mg, 750 mg or 1000 mg of levetiracetam;
Excipients: crospovidone, povidone, colloidal anhydrous silicon dioxide, magnesium stearate;
tablets 250 mg: hypromellose, macrogol, titanium dioxide (E 171), talc, indigo carmine (E 132);
500 mg tablets: hypromellose, macrogol, titanium dioxide (E 171), talc, yellow iron oxide (E 172);
tablets 750 mg: hypromellose, macrogol, titanium dioxide (E 171), talc, yellow sunset FCF (E 110), iron oxide red (E 172);
tablets 1000 mg: hypromellose, macrogol, titanium dioxide (E 171), talc.
Hypersensitivity to levetiracetam or other pyrrolidone derivatives, as well as to any excipients of the drug.
Levetiracetam tablets Mode of application
The tablets are taken orally with a sufficient amount of liquid, regardless of the meal. Divide the daily dose into 2 equal doses.
Levetiracetam tablets Application features
Levetiracetam should not be used during pregnancy, except in cases of extreme necessity, as well as in women of reproductive age who do not use contraception.
The drug in the form of tablets is not recommended for use in children under 6 years of age.
Studies of the effect of the drug on the ability to drive vehicles or other mechanisms have not been carried out. Due to possible individual sensitivity, some patients may notice drowsiness and other symptoms associated with exposure to the central nervous system, especially at the beginning of treatment or during the course of increasing the dose. Therefore, such patients should be careful when engaging in activities that require increased concentration of attention, such as driving a car or working with other mechanisms.
Levetiracetam tablets Overdose
Symptoms Drowsiness, agitation, aggression, respiratory depression, depression of consciousness, coma.
Treatment. In case of acute overdose, it is necessary to flush the stomach or induce vomiting. There is no specific antidote. If necessary, symptomatic treatment is carried out, incl. using hemodialysis (up to 60% of levetiracetam and 74% of the primary metabolite are excreted).
The most commonly reported adverse reactions were nasopharyngitis, drowsiness, headache, fatigue, and dizziness. The safety profile of levetiracetam is generally similar (adults and children).
In some cases, a decrease in the effectiveness of levetiracetam has been reported with the simultaneous use of an osmotic laxative macrogol with oral levetiracetam. Therefore, macrogol should not be taken orally within one hour before and within one hour after taking levetiracetam.
The degree of absorption of levetiracetam does not depend on food, but the absorption rate is somewhat reduced if taken with food. There is no data on the interaction of levetiracetam with alcohol.
Does not require special storage conditions.
Keep out of the reach of children!
Shelf life is 3 years.